Exploring the Role of Pathophysiology of IDH-Mutant Gliomas on Current and Emerging Treatments
Released On
August 9, 2023
Expires On
August 9, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Brain Cancer, Oncology
This activity is provided by Paradigm Medical Communications, LLC.
This activity is supported by an educational grant from Servier Pharmaceuticals LLC..
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Physician Assistants — may claim a maximum of 1.0 Category 1 Credit for completing this activity
- Nurse Practitioners — may claim a maximum of 1.0 Category 1 Credit for completing this activity
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, radiation oncologists, neuro-oncologists, neurosurgeons, and neuroradiologists. It may also be of benefit to pathologists, oncology and neurology advanced practitioners, oncology nurses, and other clinicians who are interested in the management of patients with gliomas.
Program Overview
The management of gliomas is changing, and precision medicine is now becoming a reality in the treatment of IDH-mutant gliomas. This activity will review the updated World Health Organization classification of gliomas, the pathophysiology of IDH-mutant gliomas, and how these relate to current and emerging therapies, as well as the effects on patients’ quality of life after safe maximal resection and treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the pathophysiology and current classification of IDH-mutant gliomas among adults
- Outline the current guideline-recommended treatment modalities for IDH-mutant gliomas, with a focus on the use of precision medicine
- Review quality-of-life measures associated with IDH-mutant glioma treatment, with a focus on the need to weigh potential benefits and long-term effects
Faculty
Lia Moriguchi Halasz, MD
Professor and Residency Program Director
Department of Radiation Oncology
Joint Professor
Department of Neurological Surgery
University of Washington
Co-Director, Alvord Brain Tumor Center
Fred Hutchinson Cancer Center
Seattle, WA
Katherine Peters, MD, PhD, FAAN
Associate Professor, Neurology and Neurosurgery
Director of Supportive Care
Program Director, Neuro-Oncology Fellowship
Preston Robert Tisch Brain Tumor Center
Duke University School of Medicine
Durham, NC
David A. Reardon, MD
Clinical Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute
Professor
Harvard Medical School
Boston, MA
Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosures of Conflicts of Interest
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.
All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
- FACULTY
- Lia Moriguchi Halasz, MD
- Research Funding: BioMimetix JV, LLC
- Katherine Peters, MD, PhD, FAAN
- Consultant: Ono Pharmaceutical Co., Ltd.; Sapience Therapeutics, Inc.; Servier Pharmaceuticals
- Research Funding: BioMimetix Pharmaceuticals; Sapience Therapeutics, Inc.; Servier Pharmaceuticals; Varian Medical Systems, Inc.
- David A. Reardon, MD
- Advisor: AbbVie Inc.; Advantagene Inc; Agenus Inc; Amgen Inc.; AnHeart Therapeutics; Bayer Corporation; Boehringer Ingelheim International GmbH; Boston Biomedical, Inc.; Bristol-Myers Squibb; Celldex Therapeutics; Deciphera Pharmaceuticals, Inc.; DelMar Pharmaceuticals; DNAtrix; Ellipses Pharma; EMD Serono Inc.; F. Hoffmann-La Roche AG; Genenta Science; Genentech, Inc.; Imvax; INOVIO Pharmaceuticals; Janssen Research & Development, LLC; Johnson & Johnson Services, Inc; Kintara Therapeutics, Inc.; Kiyatec; Medicenna Therapeutics; Merck & Co, Inc; Merck KGaA; Monteris Medical; NEUVOGEN, Inc.; Novartis AG; Novocure GmbH; Oncorus, Inc.; OXiGENE, Inc.; Pharmac; Pyramid Bio; Regeneron Pharmaceuticals Inc; Stemline Therapeutics, Inc.; Sumitono Dainippon Pharma Co. Ltd.; Taiho Oncology, Inc.; Vivacitas Oncology, Inc., Y-mAbs Therapeutics, Inc.
- Research Funding: Acerta Phamaceuticals, LLC; Agenus Inc; Bristol-Myers Squibb; Celldex Therapeutics; EMD Serono Inc; Enterome; Epitopoietic Research Corporation; InCyte; INOVIO Pharmaceuticals; Insightec; Novartis AG; Omniox; Tragara Pharmaceuticals, Inc.
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Instructions for Participation and Credit
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the preassessment
- View the online activity in its entirety
- Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
Course Viewing Requirements
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Contact Information
If you have any questions or comments, email us at contactus@paradigmmc.com.